Daclatasvir and Sofosbuvir With Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients With Cirrhosis: A Phase III Study (ALLY-3C)
Antiviral Therapy - United Kingdom
doi 10.3851/imp3278
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2018
Authors
Publisher
International Medical Press